ZA200108039B - Aminopyrimidines as sorbitol dehydrogenase inhibitors. - Google Patents
Aminopyrimidines as sorbitol dehydrogenase inhibitors. Download PDFInfo
- Publication number
- ZA200108039B ZA200108039B ZA200108039A ZA200108039A ZA200108039B ZA 200108039 B ZA200108039 B ZA 200108039B ZA 200108039 A ZA200108039 A ZA 200108039A ZA 200108039 A ZA200108039 A ZA 200108039A ZA 200108039 B ZA200108039 B ZA 200108039B
- Authority
- ZA
- South Africa
- Prior art keywords
- alkyl
- optionally substituted
- hydroxy
- alkoxy
- fluoro
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims description 13
- 108010009384 L-Iditol 2-Dehydrogenase Proteins 0.000 title claims description 9
- 102100026974 Sorbitol dehydrogenase Human genes 0.000 title claims description 8
- 150000005005 aminopyrimidines Chemical class 0.000 title description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 1067
- 125000000217 alkyl group Chemical group 0.000 claims description 565
- 125000001153 fluoro group Chemical group F* 0.000 claims description 356
- -1 vinylenylcarbonyl Chemical group 0.000 claims description 276
- 125000003545 alkoxy group Chemical group 0.000 claims description 221
- 229910052739 hydrogen Inorganic materials 0.000 claims description 206
- 239000001257 hydrogen Substances 0.000 claims description 206
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 166
- 150000001875 compounds Chemical class 0.000 claims description 161
- 229940002612 prodrug Drugs 0.000 claims description 151
- 239000000651 prodrug Substances 0.000 claims description 151
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 127
- 125000005843 halogen group Chemical group 0.000 claims description 116
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims description 89
- 125000001424 substituent group Chemical group 0.000 claims description 78
- 150000003839 salts Chemical class 0.000 claims description 76
- 125000004076 pyridyl group Chemical group 0.000 claims description 66
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 57
- 125000003386 piperidinyl group Chemical group 0.000 claims description 39
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical group N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 38
- 229910052757 nitrogen Chemical group 0.000 claims description 38
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 37
- 125000002757 morpholinyl group Chemical group 0.000 claims description 37
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 36
- 125000004193 piperazinyl group Chemical group 0.000 claims description 36
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 36
- 125000000335 thiazolyl group Chemical group 0.000 claims description 35
- 125000002947 alkylene group Chemical group 0.000 claims description 32
- 125000002971 oxazolyl group Chemical group 0.000 claims description 32
- 229920006395 saturated elastomer Polymers 0.000 claims description 32
- 125000002541 furyl group Chemical group 0.000 claims description 31
- 125000005466 alkylenyl group Chemical group 0.000 claims description 29
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 29
- 241000124008 Mammalia Species 0.000 claims description 28
- 125000001544 thienyl group Chemical group 0.000 claims description 28
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 27
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 23
- 150000002431 hydrogen Chemical class 0.000 claims description 23
- 125000002393 azetidinyl group Chemical group 0.000 claims description 22
- 125000002785 azepinyl group Chemical group 0.000 claims description 21
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 20
- 125000002883 imidazolyl group Chemical group 0.000 claims description 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 17
- 125000005740 oxycarbonyl group Chemical group [*:1]OC([*:2])=O 0.000 claims description 17
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 17
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 16
- 229910052717 sulfur Inorganic materials 0.000 claims description 16
- 239000011593 sulfur Chemical group 0.000 claims description 16
- 125000001624 naphthyl group Chemical group 0.000 claims description 15
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 14
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 14
- 239000003288 aldose reductase inhibitor Substances 0.000 claims description 12
- 125000003282 alkyl amino group Chemical group 0.000 claims description 12
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 12
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 12
- 125000002619 bicyclic group Chemical group 0.000 claims description 12
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims description 12
- 125000005842 heteroatom Chemical group 0.000 claims description 12
- 125000005956 isoquinolyl group Chemical group 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 229910052760 oxygen Inorganic materials 0.000 claims description 12
- 239000001301 oxygen Substances 0.000 claims description 12
- 125000005493 quinolyl group Chemical group 0.000 claims description 12
- 125000000446 sulfanediyl group Chemical group *S* 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 229940118148 Aldose reductase inhibitor Drugs 0.000 claims description 10
- 208000002249 Diabetes Complications Diseases 0.000 claims description 10
- 206010012655 Diabetic complications Diseases 0.000 claims description 10
- 102100030980 Sodium/hydrogen exchanger 1 Human genes 0.000 claims description 10
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 10
- 125000004432 carbon atom Chemical group C* 0.000 claims description 10
- 206010012601 diabetes mellitus Diseases 0.000 claims description 10
- 108010093115 growth factor-activatable Na-H exchanger NHE-1 Proteins 0.000 claims description 10
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 10
- 125000001425 triazolyl group Chemical group 0.000 claims description 10
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 9
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 9
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 8
- 125000002950 monocyclic group Chemical group 0.000 claims description 8
- 125000005554 pyridyloxy group Chemical group 0.000 claims description 8
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 8
- 125000005115 alkyl carbamoyl group Chemical group 0.000 claims description 7
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 7
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 125000004043 oxo group Chemical group O=* 0.000 claims description 7
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 7
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 7
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 6
- 239000004305 biphenyl Substances 0.000 claims description 6
- 235000010290 biphenyl Nutrition 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 6
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 6
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 6
- 125000005153 alkyl sulfamoyl group Chemical group 0.000 claims description 5
- 125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 5
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 4
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 claims description 4
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 3
- 208000028867 ischemia Diseases 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- NLUNLVTVUDIHFE-UHFFFAOYSA-N cyclooctylcyclooctane Chemical group C1CCCCCCC1C1CCCCCCC1 NLUNLVTVUDIHFE-UHFFFAOYSA-N 0.000 claims description 2
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N EtOH Substances CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 102
- 238000000034 method Methods 0.000 claims 13
- 150000003254 radicals Chemical class 0.000 claims 9
- 125000004306 triazinyl group Chemical group 0.000 claims 7
- ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 claims 6
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims 6
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 claims 6
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 claims 5
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 4
- 125000005090 alkenylcarbonyl group Chemical group 0.000 claims 4
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims 4
- 125000004414 alkyl thio group Chemical group 0.000 claims 3
- 125000001041 indolyl group Chemical group 0.000 claims 3
- 239000012442 inert solvent Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 238000005342 ion exchange Methods 0.000 claims 3
- XONPDZSGENTBNJ-UHFFFAOYSA-N molecular hydrogen;sodium Chemical compound [Na].[H][H] XONPDZSGENTBNJ-UHFFFAOYSA-N 0.000 claims 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims 3
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims 3
- 125000004588 thienopyridyl group Chemical group S1C(=CC2=C1C=CC=N2)* 0.000 claims 3
- AEOZCEMLLBCHQZ-HSHFZTNMSA-N (2r)-2-hydroxypropanimidamide;hydrochloride Chemical compound Cl.C[C@@H](O)C(N)=N AEOZCEMLLBCHQZ-HSHFZTNMSA-N 0.000 claims 2
- VZLKQEPNZIWSFF-UHFFFAOYSA-N 1-pyrrolidin-1-ylpiperidine Chemical compound C1CCCN1N1CCCCC1 VZLKQEPNZIWSFF-UHFFFAOYSA-N 0.000 claims 2
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 150000002148 esters Chemical class 0.000 claims 2
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 claims 2
- 125000006085 pyrrolopyridyl group Chemical group 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- SXQFCVDSOLSHOQ-UWTATZPHSA-N (R)-(+)-Lactamide Chemical compound C[C@@H](O)C(N)=O SXQFCVDSOLSHOQ-UWTATZPHSA-N 0.000 claims 1
- HNAGHMKIPMKKBB-UHFFFAOYSA-N 1-benzylpyrrolidine-3-carboxamide Chemical compound C1C(C(=O)N)CCN1CC1=CC=CC=C1 HNAGHMKIPMKKBB-UHFFFAOYSA-N 0.000 claims 1
- CSDSSGBPEUDDEE-UHFFFAOYSA-N 2-formylpyridine Chemical compound O=CC1=CC=CC=N1 CSDSSGBPEUDDEE-UHFFFAOYSA-N 0.000 claims 1
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims 1
- 125000006414 CCl Chemical group ClC* 0.000 claims 1
- GAWIXWVDTYZWAW-UHFFFAOYSA-N C[CH]O Chemical group C[CH]O GAWIXWVDTYZWAW-UHFFFAOYSA-N 0.000 claims 1
- 101150088095 RTM2 gene Proteins 0.000 claims 1
- 125000006242 amine protecting group Chemical group 0.000 claims 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 1
- 210000000481 breast Anatomy 0.000 claims 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims 1
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- BNIPQHDMPLVAIY-UHFFFAOYSA-N ethyl 3-hydroxyprop-2-enoate;sodium Chemical compound [Na].CCOC(=O)C=CO BNIPQHDMPLVAIY-UHFFFAOYSA-N 0.000 claims 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 229930091371 Fructose Natural products 0.000 description 7
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 7
- 239000005715 Fructose Substances 0.000 description 7
- 210000005036 nerve Anatomy 0.000 description 6
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
- 239000000600 sorbitol Substances 0.000 description 4
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 3
- 150000003230 pyrimidines Chemical class 0.000 description 3
- 229940123659 Sorbitol dehydrogenase inhibitor Drugs 0.000 description 2
- 229940090865 aldose reductase inhibitors used in diabetes Drugs 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 102000016912 Aldehyde Reductase Human genes 0.000 description 1
- 108010053754 Aldehyde reductase Proteins 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000032781 Diabetic cardiomyopathy Diseases 0.000 description 1
- 206010063547 Diabetic macroangiopathy Diseases 0.000 description 1
- 206010054044 Diabetic microangiopathy Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 201000009101 diabetic angiopathy Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000037906 ischaemic injury Diseases 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 230000007830 nerve conduction Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
- C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
- C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
- C07D451/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Health & Medical Sciences (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Materials Engineering (AREA)
- Inorganic Chemistry (AREA)
- Structural Engineering (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Enzymes And Modification Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12743799P | 1999-04-01 | 1999-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200108039B true ZA200108039B (en) | 2003-07-22 |
Family
ID=22430114
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200108039A ZA200108039B (en) | 1999-04-01 | 2001-10-01 | Aminopyrimidines as sorbitol dehydrogenase inhibitors. |
Country Status (41)
Country | Link |
---|---|
US (5) | US6414149B1 (hu) |
EP (1) | EP1185275A1 (hu) |
JP (1) | JP3581103B2 (hu) |
KR (1) | KR20020005653A (hu) |
CN (1) | CN1351497A (hu) |
AP (2) | AP2005003199A0 (hu) |
AR (1) | AR020562A1 (hu) |
AU (1) | AU768720B2 (hu) |
BG (1) | BG106038A (hu) |
BR (1) | BR0009433A (hu) |
CA (1) | CA2366858A1 (hu) |
CR (1) | CR6471A (hu) |
CZ (1) | CZ20013465A3 (hu) |
DZ (1) | DZ3037A1 (hu) |
EA (1) | EA004656B1 (hu) |
EE (1) | EE200100509A (hu) |
GT (1) | GT200000038A (hu) |
HK (1) | HK1045461A1 (hu) |
HN (1) | HN2000000040A (hu) |
HR (1) | HRP20010716A2 (hu) |
HU (1) | HUP0201011A3 (hu) |
ID (1) | ID30489A (hu) |
IL (1) | IL145364A0 (hu) |
IS (1) | IS6076A (hu) |
MA (1) | MA26727A1 (hu) |
MX (1) | MXPA01009871A (hu) |
MY (1) | MY136039A (hu) |
NO (1) | NO20014642L (hu) |
NZ (1) | NZ514144A (hu) |
OA (1) | OA11856A (hu) |
PA (1) | PA8493201A1 (hu) |
PE (1) | PE20001601A1 (hu) |
PL (1) | PL350884A1 (hu) |
SK (1) | SK13532001A3 (hu) |
TN (1) | TNSN00065A1 (hu) |
TR (1) | TR200102810T2 (hu) |
UA (1) | UA71951C2 (hu) |
UY (1) | UY26089A1 (hu) |
WO (1) | WO2000059510A1 (hu) |
YU (1) | YU71101A (hu) |
ZA (1) | ZA200108039B (hu) |
Families Citing this family (71)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1185275A1 (en) * | 1999-04-01 | 2002-03-13 | Pfizer Products Inc. | Aminopyrimidines as sorbitol dehydrogenase inhibitors |
EP1326591A2 (en) * | 2000-10-18 | 2003-07-16 | Pfizer Products Inc. | Combination of statins and sorbitol dehydrogenase inhibitors |
SE0003795D0 (sv) | 2000-10-20 | 2000-10-20 | Astrazeneca Ab | Pharmaceutically useful compounds |
SK6192003A3 (en) | 2000-11-30 | 2004-07-07 | Pfizer Prod Inc | Combination of GABA agonists and sorbitol dehydrogenase inhibitors |
JPWO2002051836A1 (ja) * | 2000-12-27 | 2004-04-22 | 協和醗酵工業株式会社 | ジペプチジルペプチダーゼ−iv阻害剤 |
IL147696A0 (en) * | 2001-01-25 | 2002-08-14 | Pfizer Prod Inc | Combination therapy |
EP1247809A3 (en) * | 2001-03-30 | 2003-12-17 | Pfizer Products Inc. | Triazine compounds useful as sorbitol dehydrogenase inhibitors |
EP1389189A2 (en) | 2001-05-22 | 2004-02-18 | Neurogen Corporation | Melanin concentrating hormone receptor ligands: substituted 1-benzyl-4-aryl piperazine analogues |
GB0127929D0 (en) * | 2001-11-21 | 2002-01-16 | Celltech R&D Ltd | Chemical compounds |
AU2002351731A1 (en) * | 2001-12-14 | 2003-06-30 | Novo Nordisk A/S | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase |
WO2004000318A2 (en) | 2002-06-21 | 2003-12-31 | Cellular Genomics, Inc. | Certain amino-substituted monocycles as kinase modulators |
US7582635B2 (en) | 2002-12-24 | 2009-09-01 | Purdue Pharma, L.P. | Therapeutic agents useful for treating pain |
MY150088A (en) | 2003-05-19 | 2013-11-29 | Irm Llc | Immunosuppressant compounds and compositions |
JP4728962B2 (ja) * | 2003-05-19 | 2011-07-20 | アイアールエム・リミテッド・ライアビリティ・カンパニー | 免疫抑制化合物および組成物 |
JP2006527211A (ja) * | 2003-06-12 | 2006-11-30 | ノボ ノルディスク アクティーゼルスカブ | ホルモン感受性リパーゼの阻害剤として使用するための1−アリール−4−(アリールオキシカルボニル)−ピペラジン誘導体 |
EP1644358A2 (en) * | 2003-07-16 | 2006-04-12 | Neurogen Corporation | Biaryl piperazinyl-pyridine analogues |
TWI290140B (en) * | 2003-08-25 | 2007-11-21 | Schering Corp | 2-Substituted benzimidazole derivatives as selective melanin concentrating hormone receptor antagonists for thr treatment of obesity and related disorders |
ATE420881T1 (de) | 2003-09-17 | 2009-01-15 | Janssen Pharmaceutica Nv | Kondensierte heterocyclische verbindungen als modulatoren des serotoninrezeptors |
WO2005037284A1 (en) * | 2003-10-15 | 2005-04-28 | Pfizer Products Inc. | Sorbitol dehydrogenase inhibitor and hypertensive agent combinations |
WO2005047268A2 (en) * | 2003-11-10 | 2005-05-26 | X-Ceptor Therapeutics, Inc. | Substituted pyrimidine compositions and methods of use |
WO2005110982A2 (en) * | 2004-04-07 | 2005-11-24 | Neurogen Corporation | Substituted 1-benzyl-4-substituted piperazine analogues |
WO2005110989A1 (en) * | 2004-04-07 | 2005-11-24 | Neurogen Corporation | Substituted 1-heteroaryl-4-substituted piperazine and piperidine analogues |
TW200609219A (en) * | 2004-06-17 | 2006-03-16 | Neurogen Corp | Aryl-substituted piperazine derivatives |
MY145822A (en) * | 2004-08-13 | 2012-04-30 | Neurogen Corp | Substituted biaryl piperazinyl-pyridine analogues |
GB0420831D0 (en) | 2004-09-17 | 2004-10-20 | Glaxo Group Ltd | Novel compounds |
US20060128710A1 (en) * | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
PL1849773T3 (pl) * | 2005-02-17 | 2014-03-31 | Astellas Pharma Inc | Pochodne piperazyny do leczenia nietrzymania moczu i bólu |
US7402596B2 (en) | 2005-03-24 | 2008-07-22 | Renovis, Inc. | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof |
EP1877385A1 (en) * | 2005-05-04 | 2008-01-16 | Vertex Pharmaceuticals Incorporated | Pyrimidines and pyrazines useful as modulators of ion channels |
EP1904491A2 (en) | 2005-05-31 | 2008-04-02 | Vertex Pharmaceuticals Incorporated | Heterocycles useful as modulators of ion channels |
US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
AU2006278759B2 (en) | 2005-08-04 | 2012-08-16 | Janssen Pharmaceutica N.V. | Pyrimidine compounds as serotonin receptor modulators |
EP1915371A4 (en) * | 2005-08-19 | 2010-09-15 | Elan Pharm Inc | BREAKDOWN N-BICYCLIC SULPHONAMIDE INHIBITORS OF GAMMA LASE CRETEASE |
JP2009519933A (ja) | 2005-12-14 | 2009-05-21 | アムゲン インコーポレイティッド | ジアザ複素環式スルホンアミド誘導体およびそれらの使用法 |
JP2010513488A (ja) * | 2006-12-20 | 2010-04-30 | メルク・シャープ・エンド・ドーム・コーポレイション | ビピペリジニル化合物、その化合物を含有する組成物及び治療方法 |
PE20090422A1 (es) | 2007-04-27 | 2009-04-18 | Purdue Pharma Lp | Derivados de piperidina, piperazina o tetrahidropiridilo como antagonistas de trpv1 |
JP5372913B2 (ja) | 2007-04-27 | 2013-12-18 | パーデュー、ファーマ、リミテッド、パートナーシップ | 疼痛治療に有効な治療薬 |
NZ582934A (en) * | 2007-08-02 | 2011-10-28 | Recordati Ireland Ltd | Novel heterocyclic compounds as mglu5 antagonists |
WO2009122436A2 (en) * | 2008-03-31 | 2009-10-08 | Sun Pharmaceutical Industries Ltd. | An improved process for the preparation of morphinane analogues |
US8703962B2 (en) * | 2008-10-24 | 2014-04-22 | Purdue Pharma L.P. | Monocyclic compounds and their use as TRPV1 ligands |
US8759362B2 (en) * | 2008-10-24 | 2014-06-24 | Purdue Pharma L.P. | Bicycloheteroaryl compounds and their use as TRPV1 ligands |
WO2010065932A1 (en) * | 2008-12-05 | 2010-06-10 | Designmedix, Inc. | Modified chloroquines with single ring moiety or fused ring moiety |
EP2393780A1 (en) * | 2009-02-04 | 2011-12-14 | Recordati Ireland Limited | Heterocyclic derivatives as m-glu5 antagonists |
TWI482771B (zh) * | 2009-05-04 | 2015-05-01 | Du Pont | 磺醯胺殺線蟲劑 |
CN101619063B (zh) * | 2009-06-02 | 2011-08-10 | 华中师范大学 | 具有抗肿瘤活性的3,7,8-多取代吡啶并[4,3-d]嘧啶衍生物及制备 |
WO2011029633A1 (en) * | 2009-09-14 | 2011-03-17 | Recordati Ireland Limited | Heterocyclic mglu5 antagonists |
AR080375A1 (es) | 2010-03-05 | 2012-04-04 | Sanofi Aventis | Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida |
US10065960B2 (en) | 2010-04-02 | 2018-09-04 | Ogeda Sa | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders |
KR101878888B1 (ko) | 2010-04-02 | 2018-08-17 | 오게다 에스.에이. | 신규한 nk-3 수용체 선택적 길항제 화합물, nk-3 수용체 매개형 질환에 사용되기 위한 의약 조성물 및 방법 |
WO2011162409A1 (en) | 2010-06-22 | 2011-12-29 | Shionogi & Co., Ltd. | Compounds having trpv1 antagonistic activity and uses thereof |
AR083199A1 (es) * | 2010-09-29 | 2013-02-06 | Intervet Internationale B V | Compuestos de n-heteroarilo con unidad de puente ciclico |
CN102572513A (zh) * | 2010-12-13 | 2012-07-11 | 财团法人资讯工业策进会 | 网络协定电视互动系统、装置及其互动方法 |
PE20141531A1 (es) | 2011-06-22 | 2014-10-23 | Purdue Pharma Lp | Antagonistas de trpv1 que incluyen sustituyentes dihidroxi y sus usos |
WO2013021276A1 (en) | 2011-08-10 | 2013-02-14 | Purdue Pharma L.P. | Trpv1 antagonists including dihydroxy substituent and uses thereof |
MX367774B (es) | 2011-10-03 | 2019-09-04 | Ogeda S A | N-ACIL-5,6,7, (8-SUSTITUIDO)-TETRAHIDRO- [1,2,4] TRIAZOLO [4,3-a] PIRAZINAS QUIRALES, NOVEDOSAS, COMO ANTAGONISTAS SELECTIVOS DE RECEPTOR DE NK-3; COMPOSICIÓN FARMACÉUTICA, MÉTODOS PARA USO EN TRASTORNOS MEDIADOS POR RECEPTOR DE NK-3 Y SU SÍNTESIS QUIRAL. |
IN2012DE00661A (hu) | 2012-03-07 | 2015-08-21 | Univ Delhi | |
CN103073506B (zh) * | 2013-01-31 | 2015-03-11 | 京博农化科技股份有限公司 | 一种2-羟基-4,6-二甲基嘧啶盐酸盐的合成方法 |
WO2014141110A2 (en) * | 2013-03-14 | 2014-09-18 | Curadev Pharma Pvt. Ltd. | Aminonitriles as kynurenine pathway inhibitors |
JP2016531864A (ja) * | 2013-09-25 | 2016-10-13 | バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated | Par−2シグナル伝達経路の阻害剤として有用なイミダゾピリダジン |
FR3022784B1 (fr) * | 2014-06-26 | 2017-09-08 | Ecole Normale Superieure Lyon | Sondes moleculaires activables hydrosolubles, intermediaires pour leur synthese et procedes de detection associes |
WO2016046398A1 (en) | 2014-09-25 | 2016-03-31 | Euroscreen Sa | Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines |
WO2016045587A1 (zh) * | 2014-09-26 | 2016-03-31 | 常州寅盛药业有限公司 | 作为ns4b抑制剂的苯并呋喃类似物 |
AR102487A1 (es) | 2014-11-03 | 2017-03-01 | Bayer Pharma AG | Derivados de feniltriazol sustituido con hidroxialquilo y sus usos |
CA2996741A1 (en) | 2015-08-28 | 2017-03-09 | Udo Lange | Fused heterocyclic compounds as s1p modulators |
WO2017107754A1 (zh) * | 2015-12-22 | 2017-06-29 | 江苏恒瑞医药股份有限公司 | 苯并哌啶类衍生物、其制备方法及其在医药上的应用 |
US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
CA3022755A1 (en) | 2016-05-03 | 2017-11-09 | Carsten Schmeck | Oxoalkyl-substituted phenyltriazole derivatives and uses thereof |
US11083720B2 (en) | 2017-03-17 | 2021-08-10 | Regents Of The University Of Colorado, A Body Corporate | Indazole inhibitors of fructokinase (KHK) and methods of use in treating KHK-mediated disorders or diseases |
MX2020001057A (es) | 2017-07-28 | 2020-11-24 | Applied Therapeutics Inc | Composiciones y metodos para tratar la galactosemia. |
CN110872302B (zh) * | 2018-08-31 | 2022-09-27 | 沈阳中化农药化工研发有限公司 | 含嘧啶的螺环类化合物及其用途 |
EP3966320A4 (en) * | 2019-05-07 | 2023-10-25 | University of Miami | TREATMENT AND DETECTION OF HEREDITARY NEUROPATHIES AND ASSOCIATED DISORDERS |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3905364A1 (de) * | 1989-02-22 | 1990-08-23 | Hoechst Ag | Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als tool |
DE4025387A1 (de) * | 1990-08-10 | 1992-02-13 | Hoechst Ag | Substituierte pyrimidin-derivate, verfahren zu ihrer herstellung und ihre verwendung als reagenzien |
NZ254550A (en) | 1992-09-28 | 1997-08-22 | Pfizer | Use of nitrogen-substituted pyrimidines to prepare medicaments useful for treatment or prevention of diabetic complications |
PT791355E (pt) * | 1996-02-29 | 2002-08-30 | Pfizer | Metodo para diminuir os daos associados com a isquemia nos tecidos |
IT1285601B1 (it) | 1996-03-08 | 1998-06-18 | Bonfiglioli Riduttori Spa | Riduttore angolare a piu' stadi |
EP1185275A1 (en) * | 1999-04-01 | 2002-03-13 | Pfizer Products Inc. | Aminopyrimidines as sorbitol dehydrogenase inhibitors |
-
2000
- 2000-03-16 EP EP00909565A patent/EP1185275A1/en not_active Withdrawn
- 2000-03-16 JP JP2000609073A patent/JP3581103B2/ja not_active Expired - Fee Related
- 2000-03-16 PL PL00350884A patent/PL350884A1/xx not_active Application Discontinuation
- 2000-03-16 YU YU71101A patent/YU71101A/sh unknown
- 2000-03-16 EA EA200100933A patent/EA004656B1/ru not_active IP Right Cessation
- 2000-03-16 AP AP2005003199A patent/AP2005003199A0/xx unknown
- 2000-03-16 CA CA002366858A patent/CA2366858A1/en not_active Abandoned
- 2000-03-16 NZ NZ514144A patent/NZ514144A/en unknown
- 2000-03-16 AU AU31845/00A patent/AU768720B2/en not_active Ceased
- 2000-03-16 CN CN00807825A patent/CN1351497A/zh active Pending
- 2000-03-16 HU HU0201011A patent/HUP0201011A3/hu unknown
- 2000-03-16 CZ CZ20013465A patent/CZ20013465A3/cs unknown
- 2000-03-16 IL IL14536400A patent/IL145364A0/xx unknown
- 2000-03-16 MX MXPA01009871A patent/MXPA01009871A/es active IP Right Grant
- 2000-03-16 OA OA1200100249A patent/OA11856A/en unknown
- 2000-03-16 BR BR0009433-1A patent/BR0009433A/pt not_active IP Right Cessation
- 2000-03-16 UA UA2001096634A patent/UA71951C2/uk unknown
- 2000-03-16 EE EEP200100509A patent/EE200100509A/xx unknown
- 2000-03-16 AP APAP/P/2001/002281A patent/AP2001002281A0/en unknown
- 2000-03-16 ID IDW00200102357A patent/ID30489A/id unknown
- 2000-03-16 SK SK1353-2001A patent/SK13532001A3/sk unknown
- 2000-03-16 KR KR1020017012626A patent/KR20020005653A/ko active IP Right Grant
- 2000-03-16 WO PCT/IB2000/000296 patent/WO2000059510A1/en not_active Application Discontinuation
- 2000-03-16 TR TR2001/02810T patent/TR200102810T2/xx unknown
- 2000-03-29 DZ DZ000060A patent/DZ3037A1/xx active
- 2000-03-29 US US09/538,039 patent/US6414149B1/en not_active Expired - Fee Related
- 2000-03-29 MA MA25941A patent/MA26727A1/fr unknown
- 2000-03-29 HN HN2000000040A patent/HN2000000040A/es unknown
- 2000-03-29 TN TNTNSN00065A patent/TNSN00065A1/fr unknown
- 2000-03-30 MY MYPI20001279A patent/MY136039A/en unknown
- 2000-03-30 UY UY26089A patent/UY26089A1/es not_active Application Discontinuation
- 2000-03-30 AR ARP000101427A patent/AR020562A1/es unknown
- 2000-03-30 PE PE2000000276A patent/PE20001601A1/es not_active Application Discontinuation
- 2000-03-31 PA PA20008493201A patent/PA8493201A1/es unknown
- 2000-03-31 GT GT200000038A patent/GT200000038A/es unknown
-
2001
- 2001-09-18 IS IS6076A patent/IS6076A/is unknown
- 2001-09-25 NO NO20014642A patent/NO20014642L/no not_active Application Discontinuation
- 2001-10-01 ZA ZA200108039A patent/ZA200108039B/en unknown
- 2001-10-01 HR HR20010716A patent/HRP20010716A2/hr not_active Application Discontinuation
- 2001-10-01 CR CR6471A patent/CR6471A/es not_active Application Discontinuation
- 2001-10-23 BG BG106038A patent/BG106038A/xx unknown
-
2002
- 2002-02-28 US US10/087,869 patent/US6602875B2/en not_active Expired - Fee Related
- 2002-09-26 HK HK02107025.2A patent/HK1045461A1/zh unknown
-
2003
- 2003-03-10 US US10/384,424 patent/US6660740B1/en not_active Expired - Fee Related
- 2003-08-21 US US10/645,401 patent/US6869943B2/en not_active Expired - Fee Related
-
2004
- 2004-08-12 US US10/918,812 patent/US6936600B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200108039B (en) | Aminopyrimidines as sorbitol dehydrogenase inhibitors. | |
DE60202452C5 (de) | Pyridazinonaldose reductase inhibitoren | |
AU2004272283B2 (en) | 2,4 di (hetero) -arylamino-pyrimidine derivatives as ZAP-70 and/or Syk inhibitors | |
AU2001276521B2 (en) | Cinnoline compounds | |
WO2004087699A2 (en) | Thiazoles useful as inhibitors of protein kinases | |
EP1337271A2 (en) | Combination of gaba agonists and sorbitol dehydrogenase inhibitors | |
AU724394B2 (en) | Pyrazole derivatives | |
US6281356B1 (en) | Substituted pyrroles | |
TWI230708B (en) | Substituted pyrroles | |
CA2426592A1 (en) | Combination of statins and sorbitol dehydrogenase inhibitors | |
CA2484282A1 (en) | Pyrimidine derivatives intermediates for producing aminopyrimidines as sorbitol dehydrogenase inhibitors |